EyePoint's pivotal Phase 3 LUGANO clinical trial for DURAVYU in wet AMD failed its primary visual acuity endpoint, despite positive secondary endpoints. This unexpected outcome has led multiple analysts to significantly downgrade the stock and drastically cut price targets, indicating a major negative re-evaluation of the company's prospects.
EyePoint announced that its DURAVYU Phase 3 LUGANO trial for wet AMD failed to meet its primary visual acuity endpoint, attributing it to a 'confounding patient subgroup.' While the company highlighted positive secondary endpoints and expressed confidence, the market and analysts are focusing on the primary endpoint failure. This is a significant setback for EYPT, as the success of DURAVYU was a key driver of its valuation. In the short term, the stock has already seen a sharp reaction, and the analyst downgrades and massive price target cuts (some from $65 to $5) signal a long-term re-rating of the company's potential. Traders face a high-risk environment, with potential for further downside if the market continues to digest the implications of this clinical trial failure, despite the company's optimistic outlook for a potential NDA filing in H1 2027 pending further results.